Safety, Tolerability, and Pharmacokinetics of KP-1461 in Phase I Clinical Studies
Background: KP-1461 is a prodrug to KP-1212. KP-1212 is a viral mutagen designed to increase viral error rate. Methods: We describe 2 phase I studies: KP1461-101 (double-blind, placebo-controlled, single, escalating doses, 100 to 1600 mg study in 42 non-HIV-infected participants) and KP-1461-102 (do...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publishing
2011-08-01
|
| Serier: | Journal of the International Association of Providers of AIDS Care |
| Online adgang: | https://doi.org/10.1177/1545109711406442 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|